---
name: Esco Aster
slug: escoaster
site: both
website_domain: escoaster.com
summary: Esco Aster is a vertically integrated CDMO and CRO delivering end-to-end contract solutions from process development and GMP manufacturing through clinical research, with specialized capabilities in vaccine production, cell therapy, plasmid DNA, extracellular vesicles, and GLP toxicology.
tagline: End-to-end bioinnovation from concept to commercial production with GMP-compliant manufacturing and clinical development.
founded_year: 
employee_count_band: 
employee_count_label: 
parent_name: 
parent_slug: 
hq_country: 
tier2_domain_verified: false
updated_at: 2026-06-16T07:03:24.583Z
services_count: 5
modalities_count: 4
indications_count: 4
locations_count: 0
review_signal_gate: closed
generated_by: BioBM Editorial AI
---

# Esco Aster

End-to-end bioinnovation from concept to commercial production with GMP-compliant manufacturing and clinical development.

Listed on cdmo.directory.

## Summary

Esco Aster is a vertically integrated CDMO and CRO delivering end-to-end contract solutions from process development and GMP manufacturing through clinical research, with specialized capabilities in vaccine production, cell therapy, plasmid DNA, extracellular vesicles, and GLP toxicology.

## Services

- Preclinical In Vitro Studies
- Preclinical In Vivo Studies
- GLP Toxicology
- Clinical Trial Services
- Translational Research

## Modalities

- Vaccine
- Cell Therapy
- Gene Therapy
- Biologics (Other)

## Indications

- Infectious Disease
- Dermatology
- Respiratory
- Neurology

## Certifications

- cGMP; Identifier: cGMP-compliant; Source: https://escoaster.com/solutions/one-health-vaccines
- GLP; Identifier: GLP Toxicology; Source: https://escoaster.com/services

## Long description

## Overview

Esco Aster is a vertically integrated bioinnovation venture accelerator and contract research and manufacturing organization (CRDMO) delivering end-to-end "idea-to-exit" solutions spanning consultancy, research, CMC development, manufacturing, testing, clinical development, and strategic capital support.

## Core Capabilities

**Manufacturing & Process Development**
- cGMP-compliant vaccine development and manufacturing with single-use solutions, process scale-up/scale-down, and process validation
- Cell bank preservation for cell lines, microbial cells, and biologics
- Cell culture process development and optimization, including medium optimization and seed preparation
- Plasmid DNA manufacturing at preclinical, clinical, and commercial scales with GMP standards
- Aseptic fill-and-finish services (first in Southeast Asia/ASEAN) with USP <1207> container-closure integrity testing and in-house autoclave sterilization
- Advanced formulation solutions for inhalation-based exosome delivery (nasal spray, nebulizer, dry powder)

**Therapeutic Modalities**
- Vaccine technologies (conventional inactivated, attenuated live, subunit, VLPs, DNA, self-amplifying RNA)
- Cell therapy including CAR-T cells, CAR-NK cells, and CAR-dendritic cells with process design through GMP manufacture
- Extracellular vesicles and exosome therapeutics
- Adherent cell line creation, banking, characterization, and storage
- Plasmid DNA for gene therapy applications

**Preclinical & Clinical Services**
- GLP Toxicology studies (material production and study oversight) aligned with investment milestones
- Preclinical to clinical testing for drug efficacy determination
- Lead optimization through commercialization support for advanced therapies
- MiniTide® 3D tissue culture platform as parallel to traditional 2D and organoid approaches

**Strategic Services**
- Strategic capital support and fundraising services
- Business development and enterprise support
- Venture ecosystem partnership

## Therapeutic Areas

Serves diagnostics, therapeutics, vaccines, dermatology, dermocosmetics, cosmeceuticals, medical aesthetics, injectables, coatings, nutraceuticals, and cellular agriculture. Demonstrated commercial deployment in human and animal vaccines, dermocosmetics, cell-based nutrition, and clinical-grade stem cells and exosomes.

_Profile last updated: 2026-06-16T07:03:24.583Z. Profile facts may include AI-assisted enrichment._

Auto-generated by BioBM Editorial AI for machine-readable profile access.